MedTrace Logo

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

NCT04734379 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-06-03

No results posted yet for this study

Summary

A Phase 2a Open-Label Preliminary Safety, Tolerability, and Biomarker Study of Oral Fasudil in Patients with the 4-Repeat Tauopathies of Progressive Supranuclear Palsy-Richardson Syndrome or Corticobasal Syndrome

Conditions

Interventions

DRUG

Fasudil

Oral fasudil 180 mg/day

Sponsors & Collaborators

  • Woolsey Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Peter Ljubenkov, MD · UCSF Weill Institute for Neurosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-22
Primary Completion
2022-11-30
Completion
2023-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04734379 on ClinicalTrials.gov